R&D News | pharmaphorum

News

GLP-1 bonanza spurs big investment at CDMO CordenPharma

CordenPharma has launched a €900 million ($981 million) investment programme to prepare for an expected surge in demand for peptide production capacity – driven by GLP-1 receptor agonists.

News

Dr Fred Aslan, Artiva's president and chief executive

Artiva announces terms for its second IPO attempt

After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva Biotherapeutics is having another go.

News

Novo leads $100m financing for Alzheimer's player Asceneuron

Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.

News

Call goes out for simpler clinical trial regulation in UK

Clinical trials are strictly regulated to ensure patient safety, but the current framework in the UK is stifling early-phase clinical research, making it harder to advance novel therapies t

News

Lexeo therapy gives hope to Friedreich's ataxia patients

An experimental gene therapy developed by Lexeo Therapeutics has shown early promise in treating one of the most serious complications of the rare neurodegenerative disorder, Friedreich's a

News

UK’s Destiny Pharma hops on the AIM delisting train

Destiny Pharma has joined a growing list of UK biotechs seeking to delist from the Alternative Investments Market (AIM) and return to private ownership.

GLP-1 bonanza spurs big investment at CDMO CordenPharma

Artiva announces terms for its second IPO attempt

Novo leads $100m financing for Alzheimer's player Asceneuron

Call goes out for simpler clinical trial regulation in UK

Lexeo therapy gives hope to Friedreich's ataxia patients

UK’s Destiny Pharma hops on the AIM delisting train

Novartis CEO joins board of "responsible" AI firm Anthropic

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks